Upload
clive-bates
View
4.856
Download
4
Embed Size (px)
DESCRIPTION
Presentation on unintended consequences of excessive e-cigarette regulation.
Citation preview
Unintended consequences
Counterfactual
www.clivebates.com@clive_bates
Unintended consequences: Ban flavours
Indoor vaping ban
Control advertising?
Impose burdens, costs and restrictions
Diminishing and negative returns to regulation
Net health
Net harm
Val
ue
to
so
cie
ty
Regulatory costs, burdens and restrictions
Builds confidence
Destroys viable firms and products
Compromises design & consumer appeal
Sweet Spot
Morgan Stanley on FDA deeming regulations
The greater barriers to entry (slower approval process, higher costs, higher product standards), will ultimately take a toll onthe number of available products and rationalize the category.
This could result in the larger tobacco companies dominating the category in the future, given the burden it would place on smaller manufacturers.
Bureaucratic regulators
Predatory companies
Public health’s “useful idiots”
The Unholy Trinity
Changing perceptions – for the worse
Birth defects
Lipoid pneumonia
Third hand nicotine exposure
Ultrafine particles
Blindness
Anti-freeze
PoisoningGateway
Winning hearts and minds?
85%
65%
0%
20%
40%
60%
80%
100%
2010 2013
Believe e-cigs safer than cigarettes?
US adult smokers
Tan ASL, Bigman CA. E-cigarette awareness and perceived harmfulness: prevalence and associations with smoking-cessation outcomes. Am J Prev Med 2014; 47: 141–9.
Perceived e-cig risk in young British smokers
Trends in electronic cigarette use in young people in Great Britain over 2013-2014 Arnott, Britton, Cheeseman, Dockrell, Eastwood, Jarvis, & McNeill ASH, CR-UK, PHE 2014
Science: five orientating propositions
• Relative risk: at least 95% less harmful than smoking, probably lower, may be negligible risk.
• Bystanders: no material health risk, possible nuisance
• Adolescents: use rising with adults, vast majority of users are smokers, may be displacing smoking
• Smoking cessation: combines appeal and effectiveness and improving over time – limited studies show at least as good as pharma nicotine already.
• Promoting smoking: no sign of gateway effects or renormalising smoking.